Summary
Immunoreactive glucagon (IRG) fractions from plasma of 8 normal subjects and 4 patients with glucagon secreting tumors were studied by gel filtration techniques on Bio Gel P-30 and Sephadex G-50 columns. The pancreatic glucagon specific anti serum (30K) of Unger was utilized to measure IRG. Columns were calibrated with labelled albumin, proinsulin, insulin and glucagon. Four peaks were defined in normal and tumor bearing patients: peak I (>20000 mol. wt.), peak II (primarily 9000 mol. wt.), peak III pancreatic glucagon (3500 mol. wt.) and peak IV small glucagon (<3500 mol. wt.). Glucagonoma patients differed from our normal and reported normal subjects in that peak II contained most of the circulating IRG. The percent of IRG associated with peak II was 9.5–31.5% in normals and 39.1–61.2% in glucagonomas. Glucagon-like biological activity in an isolated hepatocyte system was demonstrated for all peaks. However, relative to immunoreactivity, peak II showed reduced activity (25–33%). Immunoassay of dilutions of all peaks revealed the probability of immuno determinants identical with porcine pancreatic glucagon. The presence of heterogeneous IRG peaks with biological glucagon-like activity suggest that the larger molecules may be prohormones. Further, it is possible that specific elevation of peak II may be a diagnostic feature of glucagonomas.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
McGavran, M., Unger, R., Recant, L., Kilo, C., Levin, M.: Glucagon secreting pancreatic tumor: A new entity. New Engl. J. Med. 274, 1408–1413 (1966)
Gleeson, M. H., Bloom, S. R., Polak, J. M., Henry, K., Dowling, R. H.: Endocrine tumor in kidney affecting small bowel structure, mobility and absorptive function. Gut 12, 773–782 (1971)
Lightman, S. L., Bloom, S. R.: Cure of insulin-dependent diabetes mellitus by removal of a glucagonoma. Brit. med. J. 1974 I, 367–368
Mallinson, C. N., Bloom, S. R., Warin, A. P., Salmon, P. R., Cox, B.: A glucagonoma syndrome. Lancet 1974 II, 1–5
Freedberg, I. M.: Case records of the mass. General Hospital. New Engl. J. Med. 292, 1117–1123 (1975)
Leichter, S. B., Pagliari, A. S., Greider, M. H., Pohl, S., Kipnis, D. M.: Uncontrolled diabetes mellitus and hyperglucagonemia associated with an islet cell carcinoma. Amer. J. Med. 58, 285–293 (1975)
Danforth, D. N., Jr., Triche, T., Doppman, J. L., Beazley, R. M., Perrino, P. V., Recant, L.: Elevated plasma proglucagonlike component with a glucagonsecreting tumor: Effect of streptozotocin. New Engl. J. Med. (in press)
Valverde, I., Villanueva, M. L., Lozano, I., Marco, J.: Presence of glucagon immunoreactivity in the globulin fraction of human plasma (“Big plasma glucagon”). J. clin. Endocr. 39, 1090–1098 (1974)
Valverde, I., Dobbs, R., Unger, R. H.: Heterogeneity of plasma-glucagon immunoreactivity in normal, depancreatized and alloxan diabetic dogs. Metabolism 24, 1021–1028 (1975)
Unger, R. H., Eisentraut, A. M., McCall, M. S.: Glucagon antibodies and an immunoassay for glucagon. Proc. Soc. exp. Biol. (N. Y.) 120, 621–623 (1959)
Davoren, P. R.: The isolation of insulin from a single cat pancreas. Biochim. biophys. Acta (Amst.) 63, 150–153 (1962)
Hunter, W. M., Greenwood, F. C.: Preparation of Iodine-131 labelled human growth hormone of high specific activity. Nature (Lond.) 194, 495–496 (1962)
Zahlten, R. N., Stratman, F. W.: The isolation of hormone-sensitive rat hepatocytes by a modified enzymatic technique. Arch. biochem. Biophys. 163, 600–608 (1974)
Christoffersen, T., Berg, T.: Glucagon control of cyclic AMP accumulation in isolated intact rat liver parenchymal cells in vitro. Biochim. biophys. Acta. (Amst.) 338, 408 (1974)
Gilman, A. G.: A protein binding assay for adenosine 3′–5′ cyclic monophosphate. Proc. nat. Acad. Sci. (Wash.) 67, 305–312 (1970)
Penhos, J. C., Smith, S., Bhathena, S., Recant, L.: (Unpublished data)
Gutman, R. A., Lazarus, N. R., Penhos, J. C., Fajans, S., Recant, L.: Circulating proinsulin-like material in patients with functioning insulinomas. New Engl. J. Med. 284, 1003–1008 (1971)
Yalow, R. S., Berson, S. A.: “Big big insulin”. Metabolism 22, 703–713 (1973)
Yalow, R. S., Wu, N.: Additional studies on the nature of big big gastrin. Gastroenterology 65, 19–27 (1973)
Murray-Lyon, I. M., Eddelston, R., Williams, R.: Treatment of multiple hormone producing malignant islet cell tumor with streptozotocin. Lancet 1968 II, 895–898
Steiner, D. F., Kemmler, W., Clark, J. L., Oyer, P. E., Rubinstein, A. H.: Endocrine pancreas. In: Handbook of physiology, Vol. 1, p. 175. Washington: American Physiol. Society 1972
Weir, G. C., Knowlton, S. D., Martin, D. B.: High molecular weight glucagon-like immunoreactivity in plasma. J. clin. Endoer. 40, 296–302 (1975)
Author information
Authors and Affiliations
Additional information
Supported in part by NIH Grant #AM 17431-02.
Rights and permissions
About this article
Cite this article
Recant, L., Perrino, P.V., Bhathena, S.J. et al. Plasma immunoreactive glucagon fractions in four cases of glucagonoma: Increased “Large glucagon — immunoreactivity”. Diabetologia 12, 319–326 (1976). https://doi.org/10.1007/BF00420975
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00420975